David Binder, MD, PhD
Assistant Professor, Radiation Oncology

Medical School:
  • MD, University of Chicago Division of the Biological Sciences The Pritzker School of Medicine (2015)
Graduate School :
  • PhD, University of Chicago (2013)
Undergraduate School:
  • BA, Cornell University (NY) (2007)
  • University of Chicago/University of Illinois College of Medicine at Chicago Program (2016)
  • University of Colorado, Chief Resident, Radiation Oncology (2020)
Department: Radiation Oncology


  • Oweida AJ, Darragh L, Phan A, Binder D, Bhatia S, Mueller A, Court BV, Milner D, Raben D, Woessner R, Heasley L, Nemenoff R, Clambey E, Karam SD. STAT3 Modulation of Regulatory T Cells in Response to Radiation Therapy in Head and Neck Cancer. J Natl Cancer Inst. 2019 Dec 1;111(12):1339-1349. PubMed PMID: 30863843
  • Zhai L, Ladomersky E, Lauing KL, Wu M, Scholtens DM, Savoor R, Zhang B, Wu JD, Horbinski C, Lukas RV, Binder DC, Wainwright DA. Commentary: preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma by Garg et al . (2017). Oncoimmunology. 2019;8(3):1548242. PubMed PMID: 30723577
  • Oweida A, Hararah MK, Phan A, Binder D, Bhatia S, Lennon S, Bukkapatnam S, Van Court B, Uyanga N, Darragh L, Kim HM, Raben D, Tan AC, Heasley L, Clambey E, Nemenoff R, Karam SD. Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration. Clin Cancer Res. 2018 Nov 1;24(21):5368-5380. PubMed PMID: 30042205
  • Ladomersky E, Zhai L, Lenzen A, Lauing KL, Qian J, Scholtens DM, Gritsina G, Sun X, Liu Y, Yu F, Gong W, Liu Y, Jiang B, Tang T, Patel R, Platanias LC, James CD, Stupp R, Lukas RV, Binder DC, Wainwright DA. IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma. Clin Cancer Res. 2018 Jun 1;24(11):2559-2573. PubMed PMID: 29500275
  • Binder DC, Ladomersky E, Lenzen A, Zhai L, Lauing KL, Otto-Meyer SD, Lukas RV, Wainwright DA. Lessons learned from rindopepimut treatment in patients with EGFRvIII-expressing glioblastoma. Transl Cancer Res. 2018 Apr;7(Suppl 4):S510-S513. PubMed PMID: 30283731
  • Zhai L, Ladomersky E, Lauing KL, Wu M, Genet M, Gritsina G, Gyorffy B, Brastianos PK, Binder DC, Sosman JA, Giles FJ, James CD, Horbinski C, Stupp R, Wainwright DA. Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival. Clin Cancer Res. 2017 Nov 1;23(21):6650-6660. PubMed PMID: 28751450
  • Zhai L, Ladomersky E, Dostal CR, Lauing KL, Swoap K, Billingham LK, Gritsina G, Wu M, McCusker RH, Binder DC, Wainwright DA. Non-tumor cell IDO1 predominantly contributes to enzyme activity and response to CTLA-4/PD-L1 inhibition in mouse glioblastoma. Brain Behav Immun. 2017 May;62:24-29. PubMed PMID: 28179106
  • Binder DC, Wainwright DA. The Boosting Potential of Bacteria in Cancer Immunotherapy. Trends Mol Med. 2017 Jul;23(7):580-582. PubMed PMID: 28583420
  • Stokes WA, Binder DC, Jones BL, Oweida AJ, Liu AK, Rusthoven CG, Karam SD. Impact of immunotherapy among patients with melanoma brain metastases managed with radiotherapy. J Neuroimmunol. 2017 Dec 15;313:118-122. PubMed PMID: 29153603
  • Oweida A, Lennon S, Calame D, Korpela S, Bhatia S, Sharma J, Graham C, Binder D, Serkova N, Raben D, Heasley L, Clambey E, Nemenoff R, Karam SD. Ionizing radiation sensitizes tumors to PD-L1 immune checkpoint blockade in orthotopic murine head and neck squamous cell carcinoma. Oncoimmunology. 2017;6(10):e1356153. PubMed PMID: 29123967
  • Binder DC, Arina A, Wen F, Tu T, Zhao M, Hoffman RM, Wainwright DA, Schreiber H. Tumor relapse prevented by combining adoptive T cell therapy with Salmonella typhimurium. Oncoimmunology. 2016 Jun;5(6):e1130207. PubMed PMID: 27471609
  • Binder DC, Davis AA, Wainwright DA. Immunotherapy for cancer in the central nervous system: Current and future directions. Oncoimmunology. 2016 Feb;5(2):e1082027. PubMed PMID: 27057463
  • Ladomersky E, Genet M, Zhai L, Gritsina G, Lauing KL, Lulla RR, Fangusaro J, Lenzen A, Kumthekar P, Raizer JJ, Binder DC, James CD, Wainwright DA. Improving vaccine efficacy against malignant glioma. Oncoimmunology. 2016 Aug;5(8):e1196311. PubMed PMID: 27622066
  • Binder DC, Fu YX, Weichselbaum RR. Radiotherapy and immune checkpoint blockade: potential interactions and future directions. Trends Mol Med. 2015 Aug;21(8):463-5. PubMed PMID: 26091823
  • Zhai L, Spranger S, Binder DC, Gritsina G, Lauing KL, Giles FJ, Wainwright DA. Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy. Clin Cancer Res. 2015 Dec 15;21(24):5427-33. PubMed PMID: 26519060
  • Mustafi D, Gleber SC, Ward J, Dougherty U, Zamora M, Markiewicz E, Binder DC, Antic T, Vogt S, Karczmar GS, Oto A. IV Administered Gadodiamide Enters the Lumen of the Prostatic Glands: X-Ray Fluorescence Microscopy Examination of a Mouse Model. AJR Am J Roentgenol. 2015 Sep;205(3):W313-9. PubMed PMID: 26295667
  • Binder DC, Engels B, Arina A, Yu P, Slauch JM, Fu YX, Karrison T, Burnette B, Idel C, Zhao M, Hoffman RM, Munn DH, Rowley DA, Schreiber H. Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer. Cancer Immunol Res. 2013 Aug;1(2):123-33. PubMed PMID: 24455752
  • Binder DC, Schreiber H. High-affinity peptide-based anticancer vaccination to overcome resistance to immunostimulatory antibodies. Oncoimmunology. 2013 Dec 1;2(12):e26704. PubMed PMID: 24563823
View All (18 Total) View Less

Practice Locations

UCHealth Radiation Oncology - Anschutz Medical Campus
1665 Aurora Ct
Aurora, CO 80045

UCHealth Radiation Oncology - Cherry Creek Medical Center
100 Cook Street
Suite 102
Denver, CO 80206

Hospital Affiliation
  • University of Colorado Hospital

Specialty Information

  • Radiation Oncology
Conditions & Treatments
  • Cancers - Radiation Therapy
  • Cancers
Clinical Interests
I have a particular interest in gastrointestinal, breast, prostate, and gynecologic malignancies. My specialization includes the most advanced treatment techniques including high dose rate brachytherapy, prostate procedures, stereotactic body radiotherapy, and gamma knife.

Care Philosophy
I value being a member of a multidisciplinary team of cancer physicians that individualize the best treatment option for each patient, while then executing care using the most up-to-date technology. I treat each patient with respect and work with them to define a treatment approach that best aligns with their goals and values. My mission is to eradicate tumors while helping patients maintain their lifestyle during and following treatment.

General Information

Medical Schools:
  • MD, University of Chicago Division of the Biological Sciences The Pritzker School of Medicine (2015)
Graduate Schools:
  • PhD, University of Chicago (2013)
Undergraduate Schools:
  • BA, Cornell University (NY) (2007)
  • University of Chicago/University of Illinois College of Medicine at Chicago Program (2016)
Residency Programs:
  • University of Colorado, Chief Resident, Radiation Oncology (2020)
Department: Radiation Oncology
Contact Us
CU Anschutz
Fitzsimons Building

13001 East 17th Place
Campus Box C290
Aurora, CO 80045

Update My Profile